Herewith three items of pandemic news you may have missed recently: Pfizer gets permission to ship fewer vials; how non-pharmaceutical interventions have varied over the course of the pandemic; and how vaccines are coping with the new virus variants. Plus … Continue reading →
Merck announced today that it is abandoning two Covid-19 candidates that it had been working on. The Phase I trials showed poor stimulation of antibodies, both neutralizing and non-neutralizing, in their trial subjects. The company said it will focus efforts … Continue reading →
Many people do not want to be associated with anything that has to do with abortion. Of specific interest here is Covid-19 vaccines that involve use of human cells derived from an aborted fetus. Now, we should be clear that … Continue reading →
Late last September, a conservationist group called Shark Allies got the press riled up about the possibility that “half a million” sharks could be killed to obtain squalene for use in Covid-19 vaccine adjuvants. NPR covered it, National Geographic covered … Continue reading →
Herewith three items of pandemic news you may have missed recently: Pfizer’s vaccine handles the UK variant just fine; how to go about producing a vaccine-evading coronavirus; and Biden will not hold back second doses. Plus the accustomed frippery. Biden … Continue reading →
I spent about 50 years doing software development, and one constant was that management always reported that projects were going to be finished in less than half the time than they were actually going to take, even if all went … Continue reading →
Herewith three items of pandemic news: the UK variant seems to spread faster in the young; what’s next in vaccines (by new contributor Doug Pardee); and the import of the PCR test cycle threshold. Plus the accustomed frippery. Cycle threshold … Continue reading →
Herewith three items of pandemic news you may have missed recently: Less accurate pulse oximeter readings for Black patients; the spreading mink pandemic; and a marketing name for the Pfizer / BioNTech vaccine. Plus the accustomed frippery. Comirnaty You may … Continue reading →
The FDA’s outside committee of experts, the VRBPAC, is meeting again today, one week after they voted to authorize the Pfizer / BioNTech vaccine. Pretty much everyone expects that the committee will give the nod to Moderna’s candidate this afternoon. … Continue reading →
Herewith three items of pandemic news you may have missed recently: How wearable computers could predict Covid-19; the complicated situation with autoantibodies; and the late-stage trial of German company CureVac’s vaccine candidate. Plus the accustomed frippery. CureVac’s candidate enters Phase … Continue reading →
Some pandemic news you may have missed recently: How the upcoming time of vaccine purgatory will go down; two vaccines that hit a snag; and an antiviral compound that blocks SARS-CoV-2 transmission in ferrets. Plus a frippery. An antiviral that … Continue reading →
Here are three more items of pandemic news you may have missed recently: US vaccine willingness is on the rise; it’s OK for infected mothers and newborns to cohabit; and the first virus authorization is imminent. Plus a frippery. First … Continue reading →
Herewith three items of pandemic news you may have missed recently: your place in the vaccine line; what is owed to trial participants who got the placebo; and hackers attacking the cold chain. Plus the accustomed frippery. Hackers going after … Continue reading →
Herewith three items of pandemic news you may have missed recently: People who shed virus for months; two online risk estimators; and the ins and outs of taking two different vaccines. Plus the usual frippery. Taking different vaccines What happens … Continue reading →
Herewith three items of pandemic news you may have missed recently: Covid tests you should not use; all about dry ice; and the imminence of shots going into arms. Plus a frippery. Vaccinations should start soon In England, regulators are … Continue reading →
